Alana Christie

Targeting renal cell carcinoma with a HIF-2 antagonist

Wenfang Chen, Haley Hill, Alana Christie et al. · Nature · 2016 · 723 citations

Medicine, Cancer Biology, Oncology +10

Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation

Payal Kapur, Samuel Peña‐Llopis, Alana Christie et al. · The Lancet Oncology · 2013 · 461 citations

Medicine, Nephrology, Oncology +15

Predictors of Rectal Tolerance Observed in a Dose-Escalated Phase 1-2 Trial of Stereotactic Body Radiation Therapy for Prostate Cancer

D. W. Nathan Kim, L. Chinsoo Cho, Christopher Straka et al. · International Journal of Radiation Oncology*Biology*Physics · 2014 · 188 citations

Medicine, Oncology, Radiation Oncology +16

HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma

Kevin D. Courtney, Yuanqing Ma, Alberto Diaz de Leon et al. · Clinical Cancer Research · 2019 · 184 citations · Full text

Medicine, Oncology, Pharmacology +16

Modeling Renal Cell Carcinoma in Mice: <i>Bap1</i> and <i>Pbrm1</i> Inactivation Drive Tumor Grade

Yifeng Gu, Shannon Cohn, Alana Christie et al. · Cancer Discovery · 2017 · 178 citations · Full text

Medicine, Genetics, Oncology +17